UGT1A1基因多态性和肠道菌群紊乱与伊立替康化疗相关性腹泻的相关性  

The correlations between UGT1A1polymorphism,intestinal dysbiosis and irinotecan chemotherapy induced diarrhea

作　　者：鱼芳 陈晓慧[1] 陈志盛[1] 李明[2] 陈骏[1] 

机构地区：[1]大连医科大学附属第二医院肿瘤内科,辽宁大连116000 [2]大连医科大学基础医学院微生态学教研室,辽宁大连116044

出　　处：《中国微生态学杂志》2016年第6期741-744,共4页Chinese Journal of Microecology

摘　　要：腹泻是伊立替康(Irinotecan,CPT-11)化疗最常见的不良反应之一,严重影响患者的生活质量和生存。研究表明,尿苷二磷酸葡醛酰转移酶1A1(UGT1A1)基因的多态性可能是影响CPT-11化疗后腹泻等不良反应的原因之一,其中UGT1A1*28是研究最为广泛的基因位点。另一方面,近年来有研究报道,CPT-11化疗后腹泻与肠道菌群紊乱有关,尤其与产β-葡萄糖醛酸酶(β-Glucuronidase)的细菌增多有关。本文就这两大方面对CPT-11化疗相关性腹泻的研究进展作一综述。Diarrhea is one of the most common side effects of irinotecan（CPT-11）chemotherapy,which affects the life quality and survival of patients seriously.Studies have shown that the polymorphism of uridine diphosphate glucuronosyltransferase 1A1（UGT1A1）gene may be related to CPT-11 chemotherapy induced diarrhea and other side effects.UGT1A1＊28is the most widely studied gene loci.On the other hand,recent studies have reported that CPT-11 chemotherapy can induce dysbiosis of intestinal microbiota,which results in the increasing ofβ-glucuronidase producing bacteria.This paper reviewed the progress in researches on CPT-11 chemotherapy induced diarrhea in regards to these two aspects.

关 键 词：伊立替康 化疗相关性腹泻 UGT1A1 肠道菌群 

分 类 号：R734.2[医药卫生—肿瘤]